New drug combo aims to block Cancer's growth signals

NCT ID NCT07446725

Not yet recruiting Disease control Sponsor: Suzhou Genhouse Bio Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental oral drugs, GH55 and GH21, taken together by people with advanced solid tumors that have a specific genetic change in the MAPK pathway. The trial has two phases: first, to find the safest dose (Phase 1), and then to see if the combination can shrink tumors or slow their growth (Phase 2). About 152 participants who have exhausted standard treatments will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GH55 and GH21 capsules (oral drugs that block cancer growth signals)
What this could lead to: If this works, it could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early, small study (Phase 1/2) focused on safety and dosing, so it is not yet known if the combination will be effective. Side effects are possible, and the drugs may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CANCER

Contacts and locations

Locations

Shanghai Goboard Cancer Hospital

Shanghai, Shanghai Municipality, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.